Senior Director Pharmacology – Drug Discovery
Denne stilling er desværre ikke længere ledig.
Se alle ledige stillinger
Hørsholm
Do You Want a Key Role with Major Impact on Gubra’s Drug Discovery Pipeline Strategy?
If you are rooted in preclinical and early drug discovery, and you are looking for an opportunity to make a difference beyond the ordinary, you have it right here.
At Gubra, we have experienced continuous success and growth since our start in 2008. Now we are ready for the next major leap forward. As such, we are establishing a dedicated pharmacology function in our biotech unit to support drug discovery projects with the design, interpretation, and execution of in vivo pharmacology studies and model development. You will head and further develop this function in close collaboration with the R&D leadership team, of which you are a member.
High-impact Role Across Strategy and Hands-on Scientific Engagement
In this newly established and versatile key role you will define and drive the pharmacology strategy for Gubra’s drug discovery projects. As leader you will show present, inspiring and motivating leadership in combination with hands-on scientific engagement, supporting discovery projects from proof-of-concept to development candidate selection.
More specifically, you will design and interpret in vivo pharmacology studies, ensure model translatability, and lead study execution at Gubra’s own CRO and at external CROs. Your primary tasks include:
PhD with 10+ Years of Experience in Preclinical and Early Drug Discovery
To succeed in this role, you must be able to think visionary while applying structure and making decisions. Additionally, you will need your optimistic “can-do, yes-it’s-possible” attitude.
Equally important is your ability to deliver top-class results through close cross-organizational collaboration, demonstrating strong communication skills - including the ability to translate complex scientific information for audiences with diverse backgrounds. Additionally, your profile includes:
Your New Workplace
Your new workplace will be Gubra’s headquarters located in the Folehave Forest in Hørsholm, Denmark. Here, you will lead a team currently consisting of two Scientists, with more to follow as you develop the pharmacology function and expand your team.
The R&D leadership team consists of the Chief Science Officer (to whom you report), the VP for Pharmaceutical Research, the Director for Project Management, the Director for Computational Drug Discovery, and the Director for Discovery and Innovation.
Contact and Application
Please apply using the ”Apply” button. The deadline is January 8, 2026. We will hold the first round of interviews during the week commencing January 19, 2026.
If you have questions regarding salary or practical matters, you are welcome to contact HR Partner, Simone Sparholt at Questions regarding role-specific details will be addressed during the interview.
We are looking forward to receiving your application.
About Gubra
is an ambitious contract research organisation (CRO) and biotech company striving for excellence at all levels. We insist on doing things efficiently – and often differently - to reach the results we aim for. Our vision is to become leaders in the fight for a more sustainable and healthier world. We do that by facilitating the discovery of new medicine, and by acting and inspiring others to fight the ongoing climate and biodiversity crises.
Gubra’s activities are focused on the early stages of drug development and are organised in two highly synergistic business areas: CRO Services and Discovery & Partnerships (D&P). We generate our revenue by performing research for life science companies as well as by partnering projects from our discovery and development pipeline.
Our therapeutic focus is within metabolic and fibrotic diseases, and we specialize in in vivo pharmacology, ex vivo assays, drug profiling, histology, stereology and whole brain and organ imaging. In addition, we offer a full palette of advanced transcriptomics. Our ML/AI-driven peptide drug discovery platform streaMLine enables us to rapidly develop a peptide hit into a non-clinical candidate ready for development. Through a constant focus on high quality, scientific excellence, speed, and solid teamwork we have established ourselves as a highly professional and competent partner in the market.
People are our greatest asset, and our team consists of +290 employees. The mix of people from different cultures and educational backgrounds combined with our entrepreneurial mindset have greatly impacted our working environment, which is characterized by entrepreneurial drive, scientific curiosity, and teamwork – we join forces!
If you are rooted in preclinical and early drug discovery, and you are looking for an opportunity to make a difference beyond the ordinary, you have it right here.
At Gubra, we have experienced continuous success and growth since our start in 2008. Now we are ready for the next major leap forward. As such, we are establishing a dedicated pharmacology function in our biotech unit to support drug discovery projects with the design, interpretation, and execution of in vivo pharmacology studies and model development. You will head and further develop this function in close collaboration with the R&D leadership team, of which you are a member.
High-impact Role Across Strategy and Hands-on Scientific Engagement
In this newly established and versatile key role you will define and drive the pharmacology strategy for Gubra’s drug discovery projects. As leader you will show present, inspiring and motivating leadership in combination with hands-on scientific engagement, supporting discovery projects from proof-of-concept to development candidate selection.
More specifically, you will design and interpret in vivo pharmacology studies, ensure model translatability, and lead study execution at Gubra’s own CRO and at external CROs. Your primary tasks include:
- Shaping Gubra’s drug discovery pipeline strategy as part of the R&D leadership team
- Providing strategic and scientific guidance on the design, coordination, and interpretation of in vivo pharmacology studies
- Establishing robust PK/PD understanding and bridging in vitro–in vivo correlations across discovery programs
- Defining and applying relevant, translational animal models to support robust, data-driven decision-making
- Building and leading a high-performing pharmacology team within the biotech unit
- Ensuring high-quality study execution and alignment with discovery objectives through close collaboration with Gubra’s internal CRO and external CRO partners
- Integrating pharmacology data into overall project strategies through effective cross-organizational collaboration and dialogue
- Providing scientific due diligence support for the evaluation of external science, assets, and innovation opportunities
- Representing externally at scientific meetings and in collaborations
PhD with 10+ Years of Experience in Preclinical and Early Drug Discovery
To succeed in this role, you must be able to think visionary while applying structure and making decisions. Additionally, you will need your optimistic “can-do, yes-it’s-possible” attitude.
Equally important is your ability to deliver top-class results through close cross-organizational collaboration, demonstrating strong communication skills - including the ability to translate complex scientific information for audiences with diverse backgrounds. Additionally, your profile includes:
- A PhD in pharmacology, physiology, or a related biomedical discipline
- Minimum 10 years of industry experience in preclinical and early drug discovery
- A strong track record in in vivo pharmacology, PK/PD relationship analysis, and translational model development
- Demonstrated ability to design, interpret, and manage in vivo studies conducted at internal or external CROs
- Strong ability to integrate pharmacological, PK/PD, and in vitro data to guide project decisions and candidate selection
- Solid understanding of pharmacokinetics and pharmacodynamics, including modelling, dose-response relationships, and translation to clinical context
- AI curiosity and preferably some experience from using AI as a tool
- Motivation for developing your leadership skills
Your New Workplace
Your new workplace will be Gubra’s headquarters located in the Folehave Forest in Hørsholm, Denmark. Here, you will lead a team currently consisting of two Scientists, with more to follow as you develop the pharmacology function and expand your team.
The R&D leadership team consists of the Chief Science Officer (to whom you report), the VP for Pharmaceutical Research, the Director for Project Management, the Director for Computational Drug Discovery, and the Director for Discovery and Innovation.
Contact and Application
Please apply using the ”Apply” button. The deadline is January 8, 2026. We will hold the first round of interviews during the week commencing January 19, 2026.
If you have questions regarding salary or practical matters, you are welcome to contact HR Partner, Simone Sparholt at Questions regarding role-specific details will be addressed during the interview.
We are looking forward to receiving your application.
About Gubra
is an ambitious contract research organisation (CRO) and biotech company striving for excellence at all levels. We insist on doing things efficiently – and often differently - to reach the results we aim for. Our vision is to become leaders in the fight for a more sustainable and healthier world. We do that by facilitating the discovery of new medicine, and by acting and inspiring others to fight the ongoing climate and biodiversity crises.
Gubra’s activities are focused on the early stages of drug development and are organised in two highly synergistic business areas: CRO Services and Discovery & Partnerships (D&P). We generate our revenue by performing research for life science companies as well as by partnering projects from our discovery and development pipeline.
Our therapeutic focus is within metabolic and fibrotic diseases, and we specialize in in vivo pharmacology, ex vivo assays, drug profiling, histology, stereology and whole brain and organ imaging. In addition, we offer a full palette of advanced transcriptomics. Our ML/AI-driven peptide drug discovery platform streaMLine enables us to rapidly develop a peptide hit into a non-clinical candidate ready for development. Through a constant focus on high quality, scientific excellence, speed, and solid teamwork we have established ourselves as a highly professional and competent partner in the market.
People are our greatest asset, and our team consists of +290 employees. The mix of people from different cultures and educational backgrounds combined with our entrepreneurial mindset have greatly impacted our working environment, which is characterized by entrepreneurial drive, scientific curiosity, and teamwork – we join forces!
Information og data
Denne ledige stilling har jobtypen "Direktør", og befinder sig i kategorien "Ledelse og personale".
Arbejdsstedet er beliggende i Hørsholm.
Jobbet er oprettet på vores service den 17.12.2025, men kan have været deaktiveret og genaktiveret igen.
- Direktør
- Hørsholm
- Torsdag den 08. januar 2026
Lignende jobs
-
Bestyrelsesposter
[xxxxx] har en database af direktører og bestyrelsesmedlemmer, som kan matche de fleste virksomheders behov for bestyrelsesmedlemmer. Vi afdækker altid først, hvad virksomheden har brug for,.Få mere info- Direktør
- Hele Danmark
-
Serviceorienteret ejendomsfunktionæ...
Få mere info- Direktør
- Helsingør
-
Konsulent til betjening af Kommunaldirektørnetværk...
Få mere info- Direktør
- Hele Danmark
-
CEO (interim)
Få mere info- Direktør
- Hele Danmark
Statistik over udbudte jobs som direktør i Hørsholm
Herunder ser du udviklingen i udbudte direktør i Hørsholm over tid. Bemærk at jobs der ikke har en bestemt geografi ikke er medtaget i tabellen. I den første kolonne ser du datoen. I den næste kolonne ser du det samlede antal direktør.
| Dato | Alle jobs som direktør |
|---|---|
| 9. januar 2026 | 1 |
| 8. januar 2026 | 1 |
| 7. januar 2026 | 1 |
| 6. januar 2026 | 1 |
| 5. januar 2026 | 1 |
| 4. januar 2026 | 1 |
| 3. januar 2026 | 1 |